This module uses fundamental data of BriaCell Therapeutics to approximate the value of its Beneish M Score. BriaCell Therapeutics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out BriaCell Therapeutics Piotroski F Score and BriaCell Therapeutics Altman Z Score analysis.
BriaCell
Beneish M Score
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Invested Capital
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Average Inventory
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Tangible Asset Value
Ev To Operating Cash Flow
Pe Ratio
Ev To Free Cash Flow
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Roic
Payables Turnover
Roe
Return On Tangible Assets
Earnings Yield
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Fair Value
Return On Capital Employed
Return On Assets
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Sale Purchase Of Stock
Stock Based Compensation
Depreciation
Change To Account Receivables
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Investments
Issuance Of Capital Stock
Change To Inventory
Total Assets
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Total Liab
Total Current Assets
Net Receivables
Other Current Liab
Property Plant And Equipment Net
Inventory
Other Current Assets
Accumulated Other Comprehensive Income
Short Term Investments
Intangible Assets
Current Deferred Revenue
Net Invested Capital
Net Working Capital
Short Long Term Debt Total
Long Term Debt
Short Long Term Debt
Capital Stock
Short Term Debt
Common Stock
Depreciation And Amortization
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Research Development
Interest Income
Net Income Applicable To Common Shares
Net Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Gross Profit
Cost Of Revenue
Probability Of Bankruptcy
Total Debt To Capitalization is likely to climb to 0.0005 in 2024, whereas Net Debt is likely to drop (905.2 K) in 2024. At this time, BriaCell Therapeutics' ROIC is fairly stable compared to the past year. ROE is likely to climb to 5.08 in 2024, despite the fact that Book Value Per Share is likely to grow to (0.26).
At this time, it appears that BriaCell Therapeutics is a possible manipulator. The earnings manipulation may begin if BriaCell Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by BriaCell Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of BriaCell Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if BriaCell Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between BriaCell Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards BriaCell Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find BriaCell Therapeutics' degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as BriaCell Therapeutics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
The Macroaxis Fundamental Analysis modules help investors analyze BriaCell Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BriaCell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BriaCell Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.